Chinese biotech providing antibody-discovery platforms and genetically humanized mouse models for drug research.
Chinese biotech providing antibody-discovery platforms and genetically humanized mouse models for drug research.
Earns fees for supplying gene-edited mice and running research studies on them, plus up-front and milestone payments when drug makers license antibodies found with its RenMice platform. The same company is also listed in Hong Kong as 2315.
In one line: A China-based antibody-discovery/CRO platform, like a smaller Genentech-tools peer.
Moat: narrow (IP / patents, installed base). Proprietary mouse-model platform used broadly by global biopharma partners.
Headquarters: Beijing, China · Employees: 1,443
Size Biocytogen Pharmaceuticals (Beijing) (688796.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $2.09B, the 1126th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥64.59 on 18 Nov 2026.
Performance Over six months the shares fell 32.9%, against +1.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 40.5% over the last twelve months (peer median +15.8%); the operating margin is 23.6% (peer median 12.4%).
Valuation It trades at 73.0× forward earnings against a peer median of 17.0× (3rd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.8 points above its cost of capital (11.1% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.65B | CN¥1.34B | CN¥999M | CN¥720M | CN¥548M |
| Revenue growth | — | +35% | +39% | +31% | — |
| Gross profit | CN¥1.29B | CN¥940M | CN¥684M | CN¥423M | CN¥308M |
| EBITDA | CN¥541M | CN¥358M | CN¥301M | -CN¥128M | -CN¥459M |
| Net income | CN¥357M | CN¥169M | CN¥34.2M | -CN¥385M | -CN¥618M |
| Free cash flow | CN¥134M | CN¥260M | CN¥159M | -CN¥211M | -CN¥563M |
| Capital expenditure | CN¥272M | CN¥85.6M | CN¥37.8M | CN¥127M | CN¥247M |
| Total debt | n/a | CN¥919M | CN¥1.27B | CN¥1.32B | CN¥1.27B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Biocytogen Pharmaceuticals (Beijing) 688796.SS | $2.09B | -33% | +40% | 24% | 73.0× | 31.0% |
| OmniAb OABI | $741M | +97% | +91% | -116% | n/a | 60.6% |
| Charles River Laboratories CRL | $16.0B | +114% | -1% | 15% | 26.2× | 25.6% |
| AbCellera Biologics ABCL | $3.60B | +141% | +92% | -298% | n/a | n/a |
| Genscript Biotech 1548.HK | $8.69B | +133% | +53% | 12% | 294.1× | 36.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688796.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.8% | +2.9% | 3rd lowest of 21 |
| 6-month return | -32.9% | +1.6% | 2nd lowest of 21 |
| Distance from 52-week high | -58.3% | -28.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | +40.5% | +15.8% | 2nd highest of 20 |
| Operating margin | 23.6% | 12.4% | 7th highest of 21 |
| Forward P/E | 73.0× | 17.0× | 3rd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 31.0% | 13.7% | 5th most demanding of 15 |
| Growth delivered (Del g) | +41.1% | +11.4% | highest of 14 |
| Hurdle (Req g minus delivered) | -10.1 pp | -10.4 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | +1.8 pp | +0.5 pp | 9th highest of 20 |
| EV / EBITDA | 25.3× | 10.8× | most expensive of 12 |
| Net debt / EBITDA | -0.3× | 0.9× | 3rd least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Biocytogen Pharmaceuticals (Beijing) 688796.SS | China | $2.09B | -33% | +40% | 24% | 73.0× | 31.0% | +41.1% |
| Suzhou Nanomicro Technology 688690.SS | China | $2.08B | -1% | +26% | 25% | 51.5× | 33.2% | +35.2% |
| Sigurd Microelectronics 6257.TW | Taiwan | $2.10B | -28% | +18% | 24% | 11.3× | n/a | n/a |
| International Gemological Institute IGIL.NS | India | $2.05B | +33% | +21% | 58% | 26.0× | 16.3% | +37.6% |
| Firstsource Solutions FSL.NS | India | $2.04B | +13% | +20% | 12% | 20.4× | 19.2% | +13.5% |
| TIC Solutions TIC | United States | $2.15B | +14% | +39% | -1% | n/a | 32.6% | n/a |
| Heron Neutron Medical 7799.TW | Taiwan | $2.15B | +56% | n/a | -5,319% | 355.2× | n/a | n/a |
| Ardentec 3264.TWO | Taiwan | $2.17B | -26% | +32% | 30% | 11.3× | n/a | n/a |
| Sagility SAGILITY.NS | India | $2.26B | +7% | +28% | 18% | 17.0× | 11.2% | +19.5% |
| Hui Lyu Ecological Technology Groups 001267.SZ | China | $2.28B | -68% | +90% | 10% | 133.5× | n/a | n/a |
| KWS SAAT SE & Co KGaA KWS.DE | Germany | $2.30B | -11% | -1% | 13% | 12.7× | -6.0% | +4.4% |
| China Automotive Engineering Research Institute 601965.SS | China | $2.31B | -11% | +12% | 24% | 13.8× | -4.7% | +7.9% |
| Syngene International SYNGENE.NS | India | $1.88B | -8% | -6% | 13% | 70.7× | 36.4% | +11.4% |
| Jiangsu Guotai International 002091.SZ | China | $1.87B | -15% | +7% | 6% | 9.7× | -21.2% | +5.5% |
| Insperity NSP | United States | $1.86B | +55% | +2% | 0% | 19.6× | 19.4% | +9.7% |
| CECEP Environmental Protection 300140.SZ | China | $2.37B | -23% | -2% | 23% | n/a | -1.9% | +26.0% |
| Shanghai GenTech 688596.SS | China | $2.37B | +4% | +4% | 2% | 68.2× | n/a | n/a |
| Prosegur Compania de Seguridad PSG.MC | Spain | $1.82B | +10% | +4% | 6% | 12.2× | -3.7% | +6.7% |
| V2X VVX | United States | $2.45B | +9% | +13% | 4% | 11.7× | -0.5% | +26.3% |
| Beijing Orient EcoEnergy 002310.SZ | China | $1.75B | -25% | +35% | 12% | n/a | 36.0% | -47.6% |
| Hoist Finance HOFI.ST | Sweden | $1.75B | +20% | +16% | 30% | 12.2× | n/a | n/a |